drugset / Trial / NCT02542410

Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study

NCT02542410

Phase 2 Completed 10 enrolled Boston Children's Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The proposed pilot study will estimate the efficacy and safety of a novel therapeutic agent, cabergoline, with a clinical standard therapy, norethindrone acetate, for the treatment of endometriosis-associated pain in young women with endometriosis.

Timeline

Start
2016-05
Primary completion
2018-09
Completion
2018-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabergoline Small molecule 0.5 mg Oral
Comparator Norethindrone Unknown 5 mg Oral

Indications